UNITED THERAPEUTICS CORP

United Therapeutics’ CEO’s disciplined 10‑b‑5‑1 trades signal confidence and steady growth, offering investors insight into insider confidence and the company’s biotech prospects.

Insider trading at United Therapeutics: CEO Martine Rothblatt’s option exercise and trust sales signal confidence in a strong pulmonary hypertension leader.

United Therapeutics CEO Martine Rothblatt’s recent insider trades reveal a routine 10b‑5‑1 plan, modest buying, and balanced selling—offering insight into executive confidence without shaking the stock’s value.

United Therapeutics insider buy: CEO Martine A. Rothblatt’s 9,500‑share purchase shows confidence in the biotech’s growth and aligns executive‑shareholder interests.

United Therapeutics insider buys and sells reveal CEO Martine Rothblatt’s disciplined 10(b)(5)(1) plan—signaling confidence, minimal dilution, and future stock‑sale timing.

United Therapeutics insider trades reveal strategic capital rebalancing—Malcolm Jan’s modest buys vs. CEO Rothblatt’s 10(b)(5)(1) sales—offering investors insight into potential pipeline shifts while fundamentals stay strong.

CEO Martine Rothblatt’s latest 10(b)(5)(1) trade shows steady divestiture at United Therapeutics, revealing long‑term confidence amid gradual share sell‑off.

United Therapeutics CEO’s $13.5 M 10b5‑1 sale shows confidence in rising stock and fuels investor insight on future growth.

United Therapeutics insider trading: CEO Martine Rothblatt’s June 2026 10(b)(5)(1) plan moves reveal confidence in rising stock and potential volatility from option expirations.

United Therapeutics insider trading: CEO Martine Rothblatt’s buy‑sell moves signal confidence, not a sell‑off, and hint at potential undervaluation for investors.